Summary
Eli Lilly & Company (LLY) filed an 8-K on May 6, 2013, to announce a temporary medical leave of absence for its Chairman, President, and CEO, John Lechleiter, Ph.D. The leave is effective May 13, 2013, to undergo surgery for a dilated aorta, with an expected full recovery and return later in the summer. During Dr. Lechleiter's absence, Derica W. Rice, Executive Vice President of Global Services and Chief Financial Officer, will step in as Acting Chief Executive Officer. Additionally, Ellen R. Marram, the Lead Independent Director, will serve as Acting Chairperson of the Board. This filing provides crucial information regarding leadership continuity during a temporary period of executive absence.
Key Highlights
- 1CEO John Lechleiter taking temporary medical leave starting May 13, 2013, for scheduled surgery.
- 2Dr. Lechleiter is expected to make a full recovery and return to his duties later in the summer.
- 3Derica W. Rice, CFO, appointed as Acting Chief Executive Officer during Dr. Lechleiter's absence.
- 4Ellen R. Marram, Lead Independent Director, appointed as Acting Chairperson of the Board.
- 5The company has established interim leadership to ensure operational continuity.
- 6No disclosure required regarding agreements or transactions for Mr. Rice assuming responsibilities.